GD1

GD1 (also known as [123I]GD1 in its radiolabeled form) is a small-molecule radiopharmaceutical based on a rucaparib-like scaffold that targets poly(ADP-ribose) polymerase (PARP) enzymes, specifically PARP1, PARP2, and PARP3. Developed by researchers at the University of Oxford, the compound is designed for targeted radionuclide therapy (specifically Auger electron therapy) and SPECT imaging of PARP-expressing tumors, such as pancreatic ductal adenocarcinoma, non-small cell lung carcinoma, and esophageal adenocarcinoma. By incorporating the Auger electron emitter iodine-123, [123I]GD1 delivers highly localized, damaging radiation directly to the DNA of cancer cells upon binding and trapping to PARP enzymes, leading to reduced clonogenic survival with minimal damage to surrounding healthy tissues.

Other names

8-[123I]iodo-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one8-iodo-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one[123I]GD1